Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
4.660
-0.140 (-2.92%)
At close: Nov 20, 2024, 4:00 PM
4.770
+0.110 (2.36%)
After-hours: Nov 20, 2024, 7:57 PM EST
Relay Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Relay Therapeutics stock have an average target of 20.88, with a low estimate of 16 and a high estimate of 28. The average target predicts an increase of 348.07% from the current stock price of 4.66.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RLAY stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 5 | 5 | 5 |
| Buy | 3 | 3 | 4 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $19 → $20 | Strong Buy | Maintains | $19 → $20 | +329.18% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +307.73% | Oct 14, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $21 | Buy | Reiterates | $21 | +350.64% | Sep 17, 2024 |
| Stifel | Stifel | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +500.86% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $19 | Strong Buy | Maintains | $18 → $19 | +307.73% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
10.35M
from 25.55M
Decreased by -59.48%
Revenue Next Year
666.71K
from 10.35M
Decreased by -93.56%
EPS This Year
-2.71
from -2.79
EPS Next Year
-2.78
from -2.71
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.6M | 6.4M | 81.1M | ||
| Avg | 10.4M | 666,713 | 16.8M | ||
| Low | 9.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -54.7% | -38.2% | 12,059.8% | ||
| Avg | -59.5% | -93.6% | 2,419.4% | ||
| Low | -61.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.51 | -2.34 | -1.98 | ||
| Avg | -2.71 | -2.78 | -2.74 | ||
| Low | -2.90 | -3.27 | -3.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.